[Lichen sclerosus. New aspects of pathogenesis and treatment].
Lichen sclerosus et atrophicus is a chronic inflammatory disease that mainly affects women in the 5th decade. Although lichen sclerosus most often affects the anogenital region, it may occur in other cutaneous or mucosal sites. Increased fibroblast activity causes cutaneous sclerosis. Recent studies have identified lichen sclerosus as an autoantibody-mediated chronic inflammatory dermatosis. Autoantibodies against the extracellular matrix protein-1 are present in up to 80% of affected patients. In addition to the well-accepted therapy with potent corticosteroids, promising results have been obtained using calcineurin antagonists in the treatment of lichen sclerosus. Interdisciplinary management with regular monitoring can improve the clinical manifestations and quality of life.
Marini
A
A
Hautklinik, Heinrich-Heine-Universität, Düsseldorf.
Blecken
S
S
Ruzicka
T
T
Hengge
U R
UR
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D065095:Calcineurin Inhibitors; D006801:Humans; D018459:Lichen Sclerosus et Atrophicus / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D014930:Women
D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors